Introduction
A balance between cell proliferation and apoptosis is vital for tissue homeostasis. Maintenance of liver size is a notable example of homeostasis which is critically regulated by numerous growth factors and cytokines (Michalpoulos and DeFrances, 1997.) Among these factors, interleukin-6 (IL-6) is a major growth regulator in the liver following toxic damage, hepatitis, and surgical resection (Kovalovich et al., 2000; Oyanagi et al., 1999; Malasuranera et al., 1997) . For example, in IL-6 knock-out mice, DNA synthesis after partial hepatectomy or toxic carbon tetrachloride (CCl 4 ) treatment is severely impaired and activation of STAT3 does not occur (Cressman et al,. 1996; Yamada et al., 1997) . However, injection of sucient IL-6 can correct defects in DNA synthesis, hepatocyte regeneration, and liver damage. IL-6 pretreatment can also reduce hepatocyte apoptosis in IL-6 null mice following CCl 4 . Thus IL-6 is crucial to liver regenerative responses and cannot be substituted with other endogenously produced cytokines. Maione et al. (1998) recently generated double transgenic mice expressing both human IL-6 and IL-6 receptor a subunit in the liver parenchyma. The liver tissues of transgenic mice manifested early development of hyperplastic nodules and late formation of large liver adenomas. These ®ndings support the role of IL-6 as a major cytokine responsible not only for physiological but also pathological functions. Although the importance of IL-6 in liver function is extensively investigated, the signal pathways triggered by the cytokine in hepatocytes are not explored in detail.
Currently knowledge of the signaling pathway elicited by IL-6 is largely limited to cells of hematopoietic origin. Binding of IL-6 to the a subunit of its receptor triggers the recruitment of the signal-transducing protein gp130, subsequently leading to the activation of the gp130-associated Janus kinases (JAKs) (Murakami et al., 1993; Lutticken et al., 1994; Narazaki et al., 1994) . JAKs phosphorylate gp130 at several tyrosine residues and these phosphotyrosines recruit various SH2 domaincontaining proteins, such as STATs and SHP-2 (Akira et al., 1994; Boulton et al., 1994; Sadowski et al., 1993) . These events lead to the activation of multiple signal-transduction pathways, such as the STAT, Ras/MAP kinase and PI 3-kinase. The Ras/ MAP kinase pathway may further activate the transcription factors such as ELK-1, AP-1 and NF-IL-6 (Daeipour et al., 1993) . In multiple myeloma cells, both STAT and Ras/MAP kinase signaling pathways are substantially involved in the survival and/or proliferative activities (Ogata et al., 1997; Kumar et al., 1994) . Instead, activation of MAP kinase of STAT pathway by IL-6 is link to other cellular activities such as, dierentiation, in other cell systems (Nakajima et al., 1996) .
Our recent work has demonstrated that IL-6 acts as a hepatoprotector against TGF-b1-mediated apoptosis in human hepatoma cells (Chen et al., 1999) . The anti-apoptotic eect of IL-6 is mediated by concomitant activation of the PI 3-kinase/Akt and the STAT3 pathways, but with the former likely playing a major role. The signaling pathway from PI 3-kinase to the serine/threonine protein kinase Akt/protein kinase B (PKB) is involved in certain cellular responses induced by growth factors such as insulin, platelet-derived growth factor (PDGF), epidermal growth factor (EGF), insulin-like growth factor I (IGF-I), basis ®broblast growth factor, IL-2, and IL-3 (Ahmed et al., 1997; Burgering et al., 1995; Franke et al., 1995; Kulik et al., 1997; Minshall et al., 1996) . Overexpression of the constitutively active PI 3-kinase or Akt/PKB kinase protects apoptosis induced by various stimuli (Kaumann-Zeh et al., 1997; Kennedy et al., 1997) . The tumor suppressor PTEN has been proven to have phosphatidylinositol phosphatase activity, speci®cally for the 3' position, suggesting the activation of PI 3-kinase involved in the tumorigenic process (DiCristofano et al., 2000) . Conceivably, the critical role of PI 3-kinase in tumorigenic process is likely due to its anti-apoptotic eect (Toretsky et al., 1999) .
Bcl-2 family members play a central role in regulating apoptosis (Hockenbery, 1992) . The mcl-1 gene, one of bcl-2 family members, was originally identi®ed as an early gene induced during dierentiation of ML-1 myeloid leukemia cells (Kozopas et al., 1993) . Unlike other members of the bcl-2 family proteins, Mcl-1 has an extended N-terminal domain which is rich in PEST sequences (Kozopas et al., 1993) . Overexpression of Mcl-1 delays apoptosis induced by various agents such as c-Myc overexpression, growth factor withdrawal, and other cytotoxic agents (Chao et al., 1998; Reynolds et al., 1994) . These observations imply that Mcl-1 is possibly important for some cell systems in regulating cellular survival.
Results of this study have demonstrated that the anti-apoptotic protein Mcl-1 is up-regulated by IL-6 with a transient expression manner. Transfection of cells with vectors driving antisense mcl-1 abolishes the anti-apoptotic activity of IL-6. Our results further demonstrate that the cytokine-stimulated Mcl-1 expression is mediated through a PI 3-K/Akt-, but not STAT3 or MAPK-, dependent pathway.
Results

IL-6 prevents apoptosis and up-regulates Mcl-1 in Hep3B cells
Our previous work has con®rmed that IL-6 eectively prevents TGF-b-induced apoptosis in Hep3B cells (Chen et al., 1999) . Here, whether IL-6 can aect apoptosis triggered by other inducing agents, such as retinoic acid (RA) and UV irradiation, in the same cell system is considered. According to Figure 1 , when Hep3B cells were exposed to 25 mM RA and 50 mJ/cm 2 UV, cells became 50 and 60% apoptotic, respectively, as determined by TUNEL assay. Pre-treating cells with 20 ng/ml IL-6 partially reduced both RA-and UVinduced apoptotic cells. Although IL-6 exerted a varied anti-apoptotic activity against dierent agents, it appears to be a critical cytokine exerting cytoprotection in hepatic cells.
To investigate how IL-6 aects the regulation of the Bcl-2 family proteins, Hep3B cells were serum-starved for 24 h and then exposed to 10 ng/ml IL-6 for various periods as indicated. Western blotting revealed that upon IL-6 stimulation, the level of Mcl-1 protein rapidly increased at 1 h, and peaked at 3 ± 6 h (increasing around 3 ± 4-fold compared to the control), then declined (Figure 2a ). In contrast, the levels of other Bcl-2 family members such as Bcl-xL/S and Bax were little aected. However, the expression of Bcl-2 protein in Hep3B cells was not detected (data not shown). Whether the level of Mcl-1 would change with varying concentration of IL-6 was further investigated.
Figure 1 IL-6 prevents apoptosis in hepatoma cells. Hep3B cells, which had been starved for serum for 24 h, were pre-treated with IL-6 for 1 h and followed by TGF-b1 (5 ng/ml), retinoic acid (25 mM), or UV irradiation (50 mJ/cm 2 ) for further 24, 48 and 16 h, respectively. After that, apoptotic cells were determined by TUNEL assay kit (Boehringer Mannheim) according to the manufacturer's instructions. Data from three independent experiments are presented as means plus standard deviations Notably, upon 0.1 ng/ml IL-6 stimulation, the level of Mcl-1 increased signi®cantly (Figure 2b) . Expression of Mcl-1 was maximized at the concentration of 10 ng/ml (Figure 2b ). Both Bcl-xL/S and Bax protein levels were unaltered, even on treatment with 100 ng/ml of IL-6.
To examine whether the rapid change of Mcl-1 protein levels by IL-6 was probably caused by changes in the expression of mRNA, total RNA was isolated from Hep3B cells that had been exposed to 10 ng/ml of IL-6 for dierent time periods. Northern blotting analysis found that the mcl-1 mRNA (both 3.9-and 2.5-kb transcripts) was rapidly induced. The induction of mcl-1 mRNA was transient and peaked at 2 ± 3 h with roughly a 4 ± 6-fold increase Figure 3a) . The IL-6-stimulated mcl-1 mRNA expression was dose-dependent ( Figure 3b ). However, the mcl-1 mRNA was still induced by IL-6 in the presence of cycloheximide, suggesting that de novo protein synthesis was not required for this process (data not shown). The kinetics of Mcl-1 induction by IL-6 is similar to that by the phorbol ester TPA, which peaked at 3 h as reported previously (Yang et al., 1996) .
Mcl-1 plays a role in the IL-6-mediated anti-apoptotic activity
To further demonstrate whether Mcl-1 plays a role in mediating the anti-apoptotic activity of IL-6, experiments were designed to reduce the endogenous level of cellular Mcl-1 and examine its in¯uence on the survival of aected cells. Initially, we tried to establish a stable Tet-o inducible cell line that could express the antisense mcl-1. However, following several rounds of stable clone selection, none of the clones that survived could express antisense mcl-1. This was probably because of some leaky expression of the cytotoxic antisense mcl-1 in the presence of tetracycline. Thus, a transient-transfection death assay was conducted to Figure 3 IL-6 treatment increases mcl-1 mRNA levels. Hep3B cells were treated (a) for dierent time intervals or (b) with various concentrations of IL-6, and then their total RNA was isolated and analysed by Northern blotting with mcl-1-speci®c probe and internal control GAPDH probe investigate this issue. Hep3B cells were cotransfected with b-galactosidase expression plasmid (pCMV-b-Gal) plus either empty vectors, sense, or antisense mcl-1 vectors. Twenty-four hours after transfection, transfected cells were changed to serum-free medium for a further 12 h, and were then treated with IL-6, TGF-b, IL-6 plus TGF-b, or nothing for further 24 h. After treatment, the extent of cell death was determined as the number of surviving blue cells expressing bgalactosidase activity. As Figure 4 presents, transfection of the antisense mcl-1 vector eectively abolished the anti-cell death activity of IL-6. Notably, it was found that transfection of antisense vector resulted in less blue cells compared with the control vector, suggesting that expression of the mcl-1 antisense is cytotoxic on its own to the cells. This ®nding supports the observation of our failure in stable transfection and also agrees with our previous studies (Chao et al., 1998) . In contrast, transfection with sense mcl-1 vector was found to lead to more blue surviving cells on the dish (Figure 4) . Interestingly, sense mcl-1 vectortransfected Hep3B cells became resistant to cell death induced by TGF-b. Cumulatively, above results clearly indicate that mcl-1 gene is involved in the IL-6-mediated anti-apoptotic eect in Hep3B cells.
JAK/STAT3 and Erk1/2 activation are not required for Mcl-1 up-regulation mediated by IL-6
After examining the role of Mcl-1 in the IL-6-mediated anti-apoptotic eect, which signaling pathway(s) is/are involved in this up-regulation was investigated. Our previous work has demonstrated that STAT3 signaling pathway partially contributed to the anti-apoptotic activity of IL-6 (Chen et al., 1999) . Thus, whether the JAK/STAT3 pathway was involved in IL-6-induced Mcl-1 up-regulation was examined. To address this issue, a STAT3 dominant-negative mutant (STAT3F) carrying a tyrosine to phenylalanine mutation at position amino acid 705 (Nakajima et al., 1996) was introduced to Hep3B cells. Stable transfectants and neo control cells were analysed for their eect on endogenous STAT3 activity by determining the tyrosine-phosphorylation status of STAT3 after IL-6 stimulation. As Figure 5a illustrates, IL-6 clearly induced STAT3 activity in both parental Hep3B or neo control cells, as revealed by the rapid increase of a tyrosine-phosphorylated form of STAT3, whereas, IL-6 failed to induce activation of STAT3 in the STAT3F stable transfectants. Subsequently, the level of Mcl-1 protein in each cell line after IL-6 treatment was examined. According to Figure 5b , the up-regulation of Mcl-1 was not aected in Hep3B, neo control, or STAT3F cells upon stimulation of IL-6. However, the anti-apoptotic activity of IL-6 against TGF-b was partially abolished in STAT3F cells but not in Hep3B or neo control cells (data not shown).
To con®rm that the JAK/STAT3 pathway is not involved in the IL-6-induced Mcl-1 up-regulation, a speci®c inhibitor for JAK family kinases, the tyrphostin AG490, was utilized. As Figure 5c illustrates, pretreating Hep3B cells with AG490 signi®cantly reduced the tyrosine-phosphorylated state of STAT3 in the presence of IL-6, indicating that the IL-6-stimulated STAT3 activation through JAK. AG490 (25 and 50 mM), had little or no eect on IL-6-induced Mcl-1 expression (Figure 5d ). Together, these results suggest that JAK/STAT3 pathway, although involved in IL-6-induced cell survival, is not involved in IL-6-stimulated Mcl-1 expression.
IL-6 has been found to activate the ERK pathway in myeloma cells (Puthier et al., 1996) . Whether ERK1/2 was activated by IL-6 and involved in Mcl-1 upregulation in this cell context was assessed by using an antibody speci®c to the phosphorylated forms of ERK1/2. According to Figure Our previous investigations have demonstrated that IL-6 could activate PI 3-K and Akt pathways which mediated the anti-apoptotic signal of IL-6 in Hep3B Figure 4 Anti-sense mcl-1 attenuates IL-6-induced anti-cell death activity. Hep3B cells were co-transfected with pCMV-bgal (1 mg/6-well plate) and either an empty expression control vector, or a vector encoding sense, or anti-sense mcl-1 (4 mg/well). After 8 h of transfection, the medium was replaced with serum-free medium and incubated for 12 h, then treated with IL-6 (20 ng/ ml), TGF-b1 (5 ng/ml), IL-6 plus TGF-b1, or none. After 24 h of treatment, cells were ®xed and stained with X-gal, and bgalactosidase-positive cells in each ®eld (magni®ed 640) under microscopic examination were counted. The results shown here represent the mean+s.d. of three independent experiments performed in duplicate hepatoma cells (Chen et al., 1999) . This work seeks to investigate whether IL-6-induced Mcl-1 up-regulation is mediated through the PI 3-K/Akt pathway. To address this, two speci®c inhibitors of PI 3-kinase, wortmannin (Wort) and LY294002 (LY), were used. As shown in Figure 6a , LY and Wort signi®cantly reduced the IL-6-induced Mcl-1 protein expression at a dose of 25 mM and 50 nM, respectively. Under the identical circumstances, IL-6-stimulated PI 3-K activity was almost completely blocked by both inhibitors, as detected by the decreased phosphorylated form of Akt proteins using a speci®c antibody (Figure 6b, upper) . Total intracellular Akt proteins were not altered during drug treatment (Figure 6b, bottom) .
A pool of Hep3B stable clones expressing a constitutively active PI 3-kinase (p110*) generated previously was used to examine the Mcl-1 level with or without IL-6. Hep3B-p110* cells always expressed more Mcl-1 (approximately twofold) than did parental Hep3B cells either with or without IL-6 (Figure 6c ). Agarose gel electrophoresis analysis reveals that treating cells with PI 3-K inhibitor, Wort could alleviate the anti-apoptotic eect of IL-6 (Figure 6d ). These results suggest the predominance of PI3-kinase in IL-6-mediated upregulation of Mcl-1 and anti-apoptotic activity.
The serine/threonine protein kinase Akt is a downstream eector of PI 3-kinase and can be activated by IL-6 in Hep3B cells (Chen et al., 1999) . To assess the role of Akt in the IL-6-induced Mcl-1 increase, the eect of a dominant-negative mutant of Akt was investigated. We have generated Hep3B cells that stably express a HA-tagged kinase-defective mutant of Akt (Akt 179A) (Chen et al., 1999) , which can inhibit wild type Akt in a dominant-negatively fashion. Akt (K 7 )-8 and Akt (K 7 )-9 are two stable transfectants of Hep3B expressing a high level of such mutated Akt (Figure 7a) . The higher expresser, Akt(K 7 )-9, exhibited a marked reduction of Mcl-1 expression induced by IL-6 as compared to parental Hep3B cells (Figure 7b ). An activated form of Akt (MyrAkt) was further utilized, in which the Src myristoylation signals were fused to the Akt's N-terminus, to examine whether activated Akt is sucient to induce Mcl-1 expression. A stable clone with a high level of MyrAkt (MyrAkt-13) (Figure 7a ), displayed about a twofold increase of Mcl-1 protein level compared to parental Hep3B cells either in the presence or absence of IL-6 (Figure 7b ). Besides Akt, Etk, a member of the Btk nonreceptor tyrosine kinase family (Robinson et al., 1996) , is also a downstream eector of PI 3-kinase (Qiu et al., 1998) . Etk has been found to be required for IL-6-induced dierentiation of prostatic cancer cells (Qiu et al., 1998) . Thus, the question of whether the Etk signaling would also be involved in the IL-6-mediated Mcl-1 expression arises. To address this issue, Hep3B cells were transfected with expression vectors for wild type Etk or its kinase-defective mutant, Etk-KQ. The stable clones expressing wild type Etk and Etk-KQ were generated as described previously (Tsai et al., 2000) and their expression was checked with anti-Etk antibody (data not shown). A pool of these Hep3B stable clones expressing Etk-KQ and wild type Etk were included to study their eect on the up-regulation of Mcl-1. As Figure 7c shows, overexpression of Etk-KQ or wild type Etk did not alter the IL-6-induced Mcl-1 expression. Together, the above ®ndings suggest that the PI 3-K downstream eector Akt, but not Etk, is critical in mediating the signaling for regulating the expression of Mcl-1.
Discussion
The present ®ndings delineate a complete signaling pathway from IL-6 through PI 3-K/Akt to the mcl-1 gene and demonstrate that the signaling pathway confers resistance to apoptosis in human hepatoma cells. Many cytokines, the tumor promoter TPA, and various anticancer drugs have already been reported to induce Mcl-1 expression (Yang et al., 1996; Chao et al., 1998; Townsend et al., 1998) . However, these investigations almost all focused on the hematopoietic cells. as indicated. After treatment, cellular DNA was extracted and subjected to 2% agarose gel electrophoresis. DNA laddering was detected by staining with ethidium bromide Few if any works included the epithelial cells. This study is the ®rst to demonstrate that Mcl-1 expression is important for IL-6-mediated cytoprotection in a hepatic cell context.
In the novel system, IL-6 induced a transient Mcl-1 expression, a result which corresponds to other reports (Yang et al., 1996; Chao et al., 1998) , and this expression pattern should be due to the rapid turnover rate of Mcl-1 protein (half-life of approximately 3 h; Yang et al., 1996) . The question raised here is how such a short half-life protein can provide protection against cell death stimuli. We believe that Mcl-1 might be envisioned as being involved in providing a rapid initial response to death signal, allowing the cells time to marshal a further response. This may be supported by our ®ndings that IL-6 could induce the expression of other anti-apoptotic proteins, such as surviving, at a later time period (8 h after IL-6 treatment) in Hep3B cells (data not shown). Thus, we suggest that Mcl-1 has an early but indispensable role in the IL-6-mediated anti-apoptotic machinery.
The signaling pathways leading to the Mcl-1 expression have been investigated and were varied according to the type of cell models or stimuli employed. For example, in the ML-1 human myeloblastic leukemia cell line, the PKC/ERK pathway activation was found to be necessary for TPA-or the microtubule-disrupting agents-induced Mcl-1 expression (Townsend et al., 1998) . In human multiple myeloma cells, the survival cytokine, IL-6, increased Mcl-1 expression via the JAK/STAT pathway but not the Ras/ERK pathway (Puthier et al., 1999) . We have reported elsewhere that GM-CSF and IL-3 could activate Mcl-1 in TF-1 leukemia and Ba/F3 pro-B cells, respectively, and the Mcl-1 induction in both cell lines was mediated by the PI 3-K/Akt pathway (Wang et al., 1999a) . These studies revealed that the complexity of the signaling pathways regulating Mcl-1 expression is related to the type of stimuli and cell models used. Experimental evidence from the present work demonstrates that the JAK/STAT3 pathway was not involved in the IL-6-mediated Mcl-1 expression of human hepatoma cells. However, our ®ndings do not agree with other studies of human myeloma cells. The ®ndings of our study and others highlight the signi®cance of cellular context in determining the biological functions of STAT3. In hepatic cells, the IL-6-mediated JAK/STAT3 pathway activation has been well known to be tightly linked to the regulation of many acute-phase protein (APP) genes (Zhang et al., 1999; Wang et al., 1999b; Andrejko et al., 1998) , suggesting that the JAK/STAT3 pathway should be predominant in tissue in¯ammation. However, a minor role in cell survival is also suggested for STAT3, because blocking the STAT3 pathway could partly abolish the IL-6-mediated anti-apoptotic eect (Chen et al., 1999) . Recently, P21
Cip was reported to be transcriptionally up-regulated by STAT3, acting as an anti-apoptotic factor (Suzuki et al., 1999) . In our system, increased expression of p21 was observed upon IL-6 stimulation (data not shown). Whether p21 and Mcl-1 are induced independently by STAT3 or other pathways, and exactly how p21 promotes survival require further investigation.
The PI 3-K/Akt signaling pathway is involved in the survival eect of many growth factors and some transforming oncogenes (Skorski et al., 1997; Songyang et al., 1997) . Recent ®ndings demonstrate that the proapoptotic protein Bad (Datta et al., 1997) and procaspase 9 (Cardone et al., 1998) were the downstream targets of Akt that protects cells from apoptosis. However, Bad has a restricted tissue distribution, and not every survival signal that activates Akt stimulates Bad phosphorylation (Scheid and Duronio, 1998) . The phosphorylation inactivation of procaspase 9 by Akt is not generally observed in all cell types. It is possible that Akt may exert its antiapoptotic eect via the activation or inactivation of other cellular targets. The present study provides evidence that Mcl-1, the survival factor activated by IL-6, is another cellular target of the PI 3-K/Akt signaling pathway. Unlike the phosphorylation on Bad or procaspase 9, the PI 3-K/Akt pathway up-regulates the Mcl-1 expression at the level of transcription. The mechanism of PI 3-K/Akt pathway mediated Mcl-1 upregulation is not limited to hepatoma cells, other epithelial type cancer cells, such as prostatic cancer cells, basal cell carcinoma cells, and cervical cancer cells were also observed (data not shown). Our experimental results strongly suggest that transcriptional activation of mcl-1 gene expression by the PI 3-K/Akt pathway is an important mechanism by which IL-6 exerts its survival activity.
Materials and methods
Cell culture and transfection
Human hepatoma cell line Hep3B was cultured as described previously (Chen and Cheng, 1997) . Hep3B cells stably expressing the dominant-negative mutant of STAT3 (STAT3F), Akt (Akt(K 7 )-8, Akt(K 7 )-9) and Etk (Etk-KQ) were reported previously (Chen et al., 1997 (Chen et al., , 1999 . Transfection was performed using Lipofectamine reagent (Life Technologies) or Transfectin (Promega) according to the manufacturers' instruction. For selecting stable clones, G418 (700 mg/ml) was added to culture medium 48 h after transfection.
Antibodies and reagents
The anti-phosphotyrosine (RC20), anti-Mcl-1, anti-Bcl-xL, anti-Bax and anti-HA antibodies were purchased from Santa Cruz. Antibodies speci®c to phosphorylated STAT3, Akt, and Erk were from New England Biolabs. The anti-STAT3 antibody was from UBI. The kinase inhibitors such as, Wortmannin, LY294002, PD98059 and AG490 were obtained from Sigma.
Apoptosis assays
TUNEL assay was performed using an Apoptosis Detection kit (Boehringer Mannheim) according to the manufacturer's instructions. Apoptotic cells were visualized and quanti®ed with¯uorescence microscopy.
To detect DNA fragmentation on agarose gel electrophoresis, cells were resuspended in lysis buer containing 10 mmol/L EDTA, 0.5% Triton X-100, 10 mmol/L TrisHCl (pH 8.0) at 48C for 10 min and pelleted by centrifugation at 16 000 r.p.m. for 20 min. The supernatant was treated with RNase A and proteinase K at 378C for 1 h and then precipitated after addition of isopropanol. The fragmented DNA was detected by ethidium bromide staining.
Immunoblotting
Cells were lysed in a lysis buer (50 mM Tris-HCl, 150 mM NaCl, 1 mM EGTA, 1% NP-40, 1 mM NaF, 1 mM Na 3 VO 4 , 1 mM phenylmethylsulfonyl¯uoride, 1 mg/ml aprotinin and leupeptin, pH 7.4) for 20 min on ice. The lysates were centrifuged at 14 500 r.p.m. for 20 min at 48C, and, then, protein concentrations were determined by using a commercial BCA kit (PIERCES Co.). A 50 mg sample of each lysate was subjected to a 12% SDS-polyacrylamide gel electrophoresis. Finally, proteins were then transferred to nitrocellulose paper and immunoblotted with antibodies indicated in text. Detection was performed using ECL (Amersham).
Northern blotting
Total RNA was isolated from cultured cells by a previously described method (Kuo et al., 1996) . A 20 mg portion of total RNA was resolved on a 1% formaldehyde-agarose gel and blotted onto nitrocellulose ®lter by the standard procedure. The blot was then probed sequentially with various a-32 PdCTP-labeled DNA fragments by the random-priming method. After overnight hybridization at 428C with standard buer containing 50% formamide, the blot was washed once in 26SSC (16SSC is 0.15 M NaCl plus 0.015 M sodium citrate)-0.1% SDS and twice in 0.2% 6SSC-0.1% SDS at 558C and subjected to either autoradiography or direct quantitation with a PhosphorImager (Molecular Dynamics).
Transient transfection and LacZ cell death assay
Hep 3B cells were plated 24 h before transfection at a density of 1610 4 cells/well in a 6-well plate. Cells were co-transfected with pCMV-bgal (1 mg) plasmid, which expresses b-galactosidase, and plasmids containing the sense, antisense mcl-1 (4 mg), or pCDNA3 control vector using Transfectin transfection reagent (Promega Co.) Transfections were performed in duplicate. Twenty-four hours after transfection, the cell medium was replaced with fresh serum-free medium for 12 h and then the cells were treated with IL-6, TGF-b, IL-6 plus TGF-b, or nothing. After 24 h treatment, cells were harvested, washed, and ®xed in PBS containing 2% formaldehyde and 0.2% glutaldehyde. These cells were washed twice with PBS, resuspended in staining solution containing PBS (pH 7.4), 1 mM MgCl 2 , 10 mM K 4 Fe (CN) 6 , 10 mM K 3 Fe(CN) 6 and 1 mM X-gal (added just before use) for 4 ± 24 h, and washed twice with PBS. The b-galactosidasepositive cells in each well were counted.
